Evidence map›Paper›PMID 29242301›Full record

ArticleHaematologica2018

Eve M Coulter, Andrea Pepper, Silvia Mele, Najeem'deen Folarin, William Townsend, Kirsty Cuthill, Elizabeth H Phillips, Piers E M Patten, Stephen Devereux

Open access · goldAbstract read
In one paragraph

Article in Haematologica, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.3field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. B cell receptor (BCR) endocytosis.Progress in molecular biology and translational science · 2023
    Review
  6. Review
  7. The Ins and Outs of Antigen Uptake in B cells.Frontiers in immunology · 2022
    Review
  8. Review
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Eve M CoulterSchool of Cancer and Pharmaceutical Sciences, Faculty of Life Sciences and Medicine, King's College London eve.coulter@kcl.ac.uk.
Andrea PepperBrighton and Sussex Medical School, Medical research Building, University of Sussex, Brighton.
Silvia MeleSt John's Institute of Dermatology, Department of Genetics and Molecular Medicine, King's College London.
Najeem'deen FolarinDepartment of Haematological Medicine, Kings College Hospital, London, UK.
William TownsendSchool of Cancer and Pharmaceutical Sciences, Faculty of Life Sciences and Medicine, King's College London.
Kirsty CuthillDepartment of Haematological Medicine, Kings College Hospital, London, UK.
Elizabeth H PhillipsSchool of Cancer and Pharmaceutical Sciences, Faculty of Life Sciences and Medicine, King's College London.
Piers E M PattenSchool of Cancer and Pharmaceutical Sciences, Faculty of Life Sciences and Medicine, King's College London.
Stephen DevereuxDepartment of Haematological Medicine, Kings College Hospital, London, UK.
King's College London · GBKing's College Hospital · GBBrighton and Sussex Medical School · GB

Funding

Department of Health
6 · The paper itself

Abstract

B-cell receptor activation, occurring within lymph nodes, plays a key role in the pathogenesis of chronic lymphocytic leukemia and is linked to prognosis. As well as activation of downstream signaling, receptor ligation triggers internalization, transit to acidified endosomes and degradation of ligand-receptor complexes. Herein, we investigated the relationship between these two processes in normal and leukemic B cells. We found that leukemic B cells, particularly anergic cases lacking the capacity to initiate downstream signaling, internalize and accumulate ligand in acidified endosomes more efficiently than normal B cells. Furthermore, ligation of either surface CD79B, a B-cell receptor component required for downstream signaling, or surface Immunoglobulin M (IgM) by cognate agonistic antibody, showed that the two molecules internalize independently of each other in leukemic but not normal B cells. Since association with surface CD79B is required for surface retention of IgM, this suggests that uncoupling of B-cell receptor internalization from signaling may be due to the dissociation of these two molecules in leukemic cells. A comparison of lymph node with peripheral blood cells from chronic lymphocytic leukemia patients showed that, despite recent B-cell receptor activation, lymph node B cells expressed higher levels of surface IgM. This surprising finding suggests that the B-cell receptors of lymph node- and peripheral blood-derived leukemic cells might be functionally distinct. Finally, long-term therapy with the Bruton's tyrosine kinase inhibitors ibrutinib or acalabrutinib resulted in a switch to an anergic pattern of B-cell receptor function with reduced signaling capacity, surface IgM expression and more efficient internalization.

Indexed as

Signal TransductionAdenineAgammaglobulinaemia Tyrosine KinaseBenzamidesCD79 AntigensClonal AnergyEndocytosisHumansImmunoglobulin MLeukemia, Lymphocytic, Chronic, B-CellPiperidinesPyrazinesPyrazolesPyrimidinesReceptors, Antigen, B-CellacalabrutinibAdenineAgammaglobulinaemia Tyrosine KinaseBenzamidesBTK protein, humanCD79 AntigensCD79B protein, humanibrutinibImmunoglobulin MPiperidinesPyrazinesPyrazolesPyrimidinesReceptors, Antigen, B-Cell

Identifiers

PMID29242301
PMCPMC5830387
OpenAlexW2775157068

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.